drugset / Trial / NCT00619372
Oral OKT3 in Combination With Beta-D-Glucosylceramide
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This clinical study is designed to evaluate the safety of oral administration of the study drug anti CD3 (OKT3) in combination with β-D glucosylceramide \[GC\] .
Timeline
- Start
- 2008-01
- Primary completion
- 2008-04
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 7.5 mg GC, PO (in the mouth) on day 1 through 5. | Unknown | 7.5 mg | Oral |
| Subject | muromonab-CD3 | Monoclonal antibody | 0.2 mg | Oral |
| Subject | muromonab-CD3 | Monoclonal antibody | 1 mg | Oral |
| Subject | muromonab-CD3 | Monoclonal antibody | 5 mg | Oral |
Indications
No indication recorded.